ER is a member of the nuclear receptor family and regulates the transformed phenotype of the majority of breast cancers. Pharmacological inhibitors of estrogen-driven signaling are effective in many of these cases 1 . Therapeutics in this class include drugs that suppress estrogen production (aromatase inhibitors and gonadotropin-releasing hormone agonists) and direct inhibitors of ER (selective ER modulators (SERMs) or selective ER degraders (SERDs)) 2 . Although most patients with ER-positive breast cancer derive a benefit from these drugs, resistance often emerges after prolonged exposure 1,3-5 . The mechanisms underlying this phenomenon are unclear, and a better understanding of acquired resistance to hormone antagonists is essential for the development of more durable and effective therapeutics.
ER is a member of the nuclear receptor family and regulates the transformed phenotype of the majority of breast cancers. Pharmacological inhibitors of estrogen-driven signaling are effective in many of these cases 1 . Therapeutics in this class include drugs that suppress estrogen production (aromatase inhibitors and gonadotropin-releasing hormone agonists) and direct inhibitors of ER (selective ER modulators (SERMs) or selective ER degraders (SERDs)) 2 . Although most patients with ER-positive breast cancer derive a benefit from these drugs, resistance often emerges after prolonged exposure 1, [3] [4] [5] . The mechanisms underlying this phenomenon are unclear, and a better understanding of acquired resistance to hormone antagonists is essential for the development of more durable and effective therapeutics.
RESULTS

ESR1 mutations in metastatic breast cancer
To identify possible genetic mechanisms underlying acquired resistance to hormonal therapy, we sought to characterize tumors from individuals with metastatic ER-positive breast cancer treated for at least 3 months with hormonal therapy and whose tumors had grown or spread to new sites while on therapy. As part of a metastatic breast tumor procurement protocol (National Clinical Trials Registry 00897702), we identified 38 of 71 samples that met these criteria and had sufficient tumor DNA for analysis. We used a targeted approach to genomic characterization, surveying for mutations and copy number alterations in 230 genes commonly mutated in cancer through massively parallel sequencing (MSKCC sequencing panel) 6 . Two cases were excluded from the analysis because they did not pass quality control testing for being from a single source. In the MSKCC cohort, we had normal DNA from white blood cells for comparison in 22 cases. Analysis of these 22 matched samples identified an average of 4.3 mutations per tumor with a mean coverage depth of ~500× (normal sample, 441×; metastatic sample, 696×) (Supplementary Table 1) . Six genes were mutated in more than 10% of the matched cases. We compared the prevalence of mutations in these genes in our set of relapsed tumors with their prevalence in The Cancer Genome Atlas (TCGA) invasive primary (untreated) breast cancer and luminal A and luminal B primary breast cancer cases and found that the prevalence of mutations in TP53, PIK3CA and GATA3 was comparable in all sets (Fig. 1a) 7 . By contrast, ESR1, RPTOR and ERBB3 mutations were detected at much higher rates in our samples than in those reported by TGCA. The fact that these mutations are enriched among tumors from patients who had relapsed while on hormonal therapy suggests that they may have a role in the development of acquired resistance. Gene copy number was also analyzed in these samples, and the genes that were frequently amplified are shown in Figure 1b . Amplification of ERBB2 (refs. 8-10) , CCND1 (ref. 11) or FGFR1 (ref. 12 ) was common and has previously been associated with hormone resistance, but these amplifications were not commonly observed to be acquired in those cases where we had information on the primary tumor. 
A r t i c l e s
The mutations in ESR1 clustered in a small region that encodes its LBD and were obvious candidates for mediating hormone resistance. In addition to the 7 tumors with these mutations out of the 22 that had matched normal DNA, 2 more tumors with mutations affecting the LBD were detected in the 14 samples without matched normal DNA (in a total of 9/36 cases). The clinical histories of these patients showed that they were treated with multiple lines of hormonal therapy for an average of 4.9 years (range of 1-10 years) ( Table 1) . Of note, all nine patients with ESR1 mutations were treated at some point with aromatase inhibitors, drugs that reduce the levels of circulating estrogens. We were able to obtain pretreatment, primary tumor samples from two of the nine patients with ESR1 mutations, and the mutation was not present in these samples in either case, although these primary tumors did harbor several other alterations that were identified in the paired metastatic sample. Of all the cases with ESR1 mutation, two cases harbored concurrent PIK3CA mutations, two cases had concurrent GATA3 mutations, and one case had both concurrent PIK3CA and GATA3 mutations. No other mutations were concurrent with ESR1 mutation. In a separate analysis of 26 ER-negative tumors, no ESR1 LBD mutation was detected (S.C., unpublished data). All ESR1 mutations affected the LBD of the receptor, and the majority specifically altered amino acid 537 or 538 in helix 12 (H12; Fig. 1c) .
The finding of LBD alterations in our small cohort of metastatic samples but not in several large whole-genome analyses of untreated, primary tumors was notable, and we sought to validate this observation in another cohort of tumors. We analyzed tumors collected from patients who enrolled in the BOLERO-2 clinical trial (NCT00863655), which studied patients with ER-positive metastatic breast cancer whose tumors had progressed during treatment with an aromatase inhibitor 13 . Most of these tumors were collected before any exposure to hormonal therapy (primary tumors); however, a subset was collected after some exposure to hormonal therapy (metastatic tumors). Among the metastatic tumors analyzed (Foundation Medicine sequencing panel; >600× average coverage), ESR1 mutations were observed in 11% of the cases (5/44), with only 3% (6/183) of the primary tumors mutated in this gene (Supplementary Fig. 1 ). Once again, mutation affecting Tyr537 or Asp538 of the LBD was frequently observed and occurred in patients with prolonged hormonal treatment (average of 4 years) ( Table 2  and Supplementary Table 2) . Although there were not sufficient mutant tumors to formally analyze the usefulness of these mutations in predicting response to therapy in the BOLERO-2 clinical trial, there did not seem to be obvious differences in how patients with mutant and wild-type ESR1 fared on the aromatase inhibitor plus placebo arm of the study. This result is not surprising, as all patients had already had tumor progression during treatment with an aromatase inhibitor. Given the strong correlation of LBD alterations in these two tumor sets with hormone-resistant disease, we set out to characterize the functional consequences of the more frequent mutations (encoding p.Asp538Gly, p.Tyr537Ser and p.Ser463Pro alterations) for ER activity and sensitivity to hormonal therapy.
ERa LBD alterations promote receptor activation
Alteration of Tyr537 to serine was previously demonstrated to promote the ERα agonist conformation and activation of its transcriptional functions 14, 15 . To determine the activity of the newly identified mutants, we used site-directed mutagenesis to introduce specific mutations into ESR1 constructs encoding HA-tagged protein. Constructs were cotransfected into breast cancer cells along with reporter plasmids carrying estrogen-responsive element (ERE)-luciferase and Renilla luciferase (pRL-TK). In ER-negative SK-BR-3 cells, the levels of luciferase activity in the absence of 17β-estradiol (E2) were highest in cells expressing the Tyr537Ser mutant (60 times wildtype levels), followed by cells expressing the Ser463Pro/Asp538Gly double mutant (30 times wild-type levels) and cells expressing the Asp538Gly mutant (15 times wild-type levels) (Fig. 2a) . The addition npg of 10 nM E2 potently induced the activities of the wild-type receptor (5 times basal wild-type levels) and the Ser463Pro mutant (3 times basal Ser463Pro levels), whereas it only weakly increased the already high levels driven by the Tyr537Ser (1.4 times basal Tyr537Ser levels), Asp538Gly (1.5 times basal Asp538Gly levels) and Ser463Pro/ Asp538Gly (1.6 times basal Ser463Pro/Asp538Gly levels) mutants. In ER-driven MCF7 cells, these assays again showed that the mutants with alterations at residues 537 and 538 had very high basal activity with modest further induction by E2 (Fig. 2a) . Expression of the Ser463Pro mutant induced modest activity in the absence of hormone and required E2 addition to achieve activity levels near those seen with alterations at residue 537 or 538 without hormone. We examined the activity of the mutants in four other cell lines (consisting of models of breast and endometrial cancer) and found in all cases that the Tyr537Ser and Asp538Gly mutants potently induced activity in the absence of hormone to near or above the levels achieved by E2 activation of wild-type receptor, whereas the Ser463Pro mutant was weakly activating (Supplementary Fig. 2a-f) . These results suggest that the alterations at residues 537 and 538 can effectively promote ER transactivation function in the absence of hormone, although mutants still bind and are responsive to ER agonists. Given the elevated activity of the mutants on an ERE reporter, we next asked whether they could activate known ER-dependent transcripts. HA-ERα constructs were transfected into MCF7 cells in hormone-depleted medium, and mRNA levels of ER target genes (GREB1, MYC, PGR, TFF1, XBP1 and CTSD) were measured. To control for potential differences in expression of the ERα constructs, mRNA levels of ER target genes were normalized to total ESR1 mRNA levels (similar data were obtained when normalized to ACTB; Supplementary Fig. 3 ). Compared to cells expressing wildtype ERα, cells expressing the Tyr537Ser, Ser463Pro;Asp538Gly and Asp538Gly mutants had significantly higher levels of GREB1, MYC, PGR and TFF1 mRNA (Fig. 2b) . To further assess whether the mutants promote transcriptional function in the absence of hormone, we performed gene expression analysis of MCF7 cells transfected with the various ERα mutant constructs in hormone-depleted medium. In comparison to wild-type ERα, the mutants differentially regulated a total of 203 genes, of which 92 were shared among the mutants. Hierarchical clustering of these genes showed that the Tyr537Ser, Asp538Gly and Ser463Pro/Asp538Gly mutants grouped together and induced a shared gene expression pattern distinct from that of the wild-type protein (Fig. 2c) . This finding is in agreement with the quantitative PCR and ERE-luciferase results, and these data, taken together, demonstrate that, in the absence of E2, the Tyr537Ser and Asp538Gly mutants activate ER transcriptional function much more potently than wild-type ERα.
Ser118 is one of the major phosphorylation sites of ERα (ref. 16 ). Phosphorylation of Ser118, located within the AF-1 domain, has been shown to modulate the ligand-independent activity of ER 17 . All mutants displayed elevated levels of Ser118 phosphorylation compared to wild-type ERα, with the Tyr537Ser and Ser463Pro/ Asp538Gly mutants showing the highest levels (Fig. 2d) . The degree to which the mutant receptors were phosphorylated corresponded with the degree to which they activated expression of luciferase in the reporter assays and induction of ER target gene expression, further suggesting that the mutants possess greater estrogenindependent activity.
Coregulators recruited by ER can either promote (coactivators) or suppress (corepressors) the transcription of ER target genes. The binding of these coregulators specifies the response of target genes to a particular receptor-ligand complex. Among these coregulators, AIB1 has a critical role as a coactivator in ER target gene expression 18, 19 . We sought to determine the effect of LBD alterations on the interaction of ER and AIB1 by coimmunoprecipitation. In comparison to wild-type ERα, the Asp538Gly mutant coimmunoprecipitated a substantially greater amount of AIB1 (Fig. 2e) . These data further suggest that the Asp538Gly mutant promotes ER function through a direct effects on ER conformation.
In the absence of ligand, ER associates with the heat shock protein 90 (HSP90) complex, which promotes its conformational stability 20 . As the ERα mutants are able to promote transcription in an estrogenindependent manner, we speculated that they might be less dependent on chaperone function for their stability. To test this hypothesis, we transfected MCF7 cells with constructs encoding HA-tagged wild-type or mutant ERα and treated cells with an ATP competitive inhibitor of HSP90, SNX2112 (ref. 21) , for 3 h. We assessed ERα protein levels by immunoblotting. The level of both the Tyr537Ser and Asp538Gly mutants were unaffected by HSP90 inhibition, whereas the levels of wild-type protein substantially decreased in a dose-dependent fashion (Fig. 2f) . In further support of our hypothesis, SNX2112 treatment in hormone-deprived medium resulted in more rapid and profound depletion of wild-type than mutant ERα ( Supplementary Fig. 4 ). These data further suggest that there are differences in the conformations and activities of wild-type and mutant ERα receptors.
The higher activities of the Tyr537Ser and Asp538Gly mutant receptors suggested that they might promote hormone-independent tumor cell growth. To test this idea, we generated stable MCF7 cell lines in which expression of HA-tagged wild-type ERα and Tyr537Ser and Asp538Gly mutants was under the control of the tetracycline promoter ( Supplementary Fig. 5 ). These MCF7 sublines were used to establish tumors in nude mice in the presence of E2 pellets that were surgically implanted in mice 3 d before injection with cells. Pellets were removed when the tumors reached a size of ~250 mm 3 to mimic estrogen deprivation therapy. To induce the expression of the HA-tagged wild-type ERα and mutant proteins in tumor cells, mice received water containing 0.2 or 0.5 mg/ml doxycycline and 1% sucrose 1 week after the removal of the E2 pellets. The growth rates of all tumors were significantly reduced during the week when estrogen and doxycycline were absent (Fig. 2g) , indicating that the tumors are dependent on ER signaling. However, inducing expression of the Tyr537Ser or Asp538Gly mutant dramatically increased tumor growth (Fig. 2g) . These data further confirm the sufficiency of the Tyr537Ser and Asp538Gly mutants in facilitating hormoneindependent ER function.
Residual activity of ERa mutants after drug inhibition
Mutations affecting residues 537 and 538 appeared to strongly promote various ER activities in the absence of ligand. One of the primary modes of treatment of ER-positive breast cancer is estrogen deprivation. Our data suggest that Asp538Gly and Tyr537Ser mutant forms of ERα can adopt an agonist confirmation irrespective of LOC728835  LOC728811  LOC645638  LOC651397   PIP  ALDOC  SERPINA3  RGS2  PGM5  DNTTIP2  S100A8  S100P  CFB  HSPA6  KRT16  KRT6A  CCDC106  MGC102966  C15ORF54  LOC642938  LOC649703  CCL2  IL28A  NLF2  IGFL1  LTB  TNF  UBD  TFF2  PGA5  PHLDA1  LOC647993  LOC643150  LOC643161  LOC647987  SYNPO2L  TMEM145  FAM26A  CALHM3  TMOD1  TUBA3C  TUBA3D  OTOF  CST1  TUBA3E  SLC45A3  VASN  ATP4A  RASD1  TH  H19  SDK2  CST5  SERPINA1  UNC5A  FHL2  FAM167A  NUDT16L1   RET  WNT11  KIF1A  PLCH2  NKD2  PGLYRP2  GDPD5  IGFBP3  ALPPL2  OXT  SOX8  SMTNL2  ECEL1  ANKDD1A  SLCO2A1  ALPL  FZD9  NPTX1  GNG13  LINCR  CPZ  MMP11  FAM43A  ADAP2  CHST8  BSN  ANXA8  C12ORF34  ZNF513  C2CD4A  HSPA7  LOC400578  KRT17 from triplicate biological replicates. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, t test. (b) MCF7 cells were transfected with constructs for HA-tagged wild-type ERα or mutants in hormone-depleted medium and collected 48 h after transfection. ERα target gene mRNA levels were measured by quantitative RT-PCR using gene-specific primers. Bars represent the means ± s.d. from triplicate technical replicates normalized to ESR1 expression. *P < 0.05; ***P < 0.001; ****P < 0.0001, t test. Data shown are representative of two biological replicates. (c) Gene expression microarray analysis was performed using RNA derived from MCF7 cells transfected with empty vector or with vector expressing GFP fused to wild-type ERα or mutants in hormone-depleted medium for 48 h. A total of 92 genes were commonly up-or downregulated by the ERα mutants, and these genes were hierarchically clustered to generate a heat map. Selected genes previously well established as estrogen-responsive genes are marked with asterisks. hormone availability. However, drugs directly targeting ER, such as tamoxifen or fulvestrant, might still be effective against the mutant forms of ERα. To test whether LBD mutants resist ER-targeted therapies, we examined the effect of 4-hydroxytamoxifen (4-OHT) or fulvestrant over a range of doses in transfected SK-BR-3 cells. Given the mixed agonist/antagonist effects of 4-OHT, a low dose of E2 (1 nM) was used to focus on the antagonist property in these experiments 22 . Consistent with previous reports, 4-OHT potently inhibited the transcriptional activity of the Tyr537Ser mutant in ERE-driven luciferase expression 23 . The drug also potently antagonized the Asp538Gly mutant, with ~70% inhibition of the activities of the Asp538Gly and Tyr537Ser mutants using 10 nM 4-OHT (Fig. 3a) . However, the amount of residual activity in these cells is also notable. To reduce ER activity to levels close to those observed with the vector-transfected cells, substantially higher doses of drug were required. We examined this phenomenon across a panel of cell lines and found similar results: 4-OHT potently antagonized the Tyr537Ser and Asp538Gly mutants, but, at lower doses (for example, 1-10 nM), there was higher residual activity than with wild-type ERα or empty vector (Supplementary Figs. 2 and 6) . Bazedoxifene, which is a third-generation SERM, exhibited similar effects as 4-OHT (data not shown). The pure anti-estrogen fulvestrant also resulted in a similar phenomenon as 4-OHT (Fig. 3b) , with low doses (1-5 nM) decreasing the activity of mutants with alteration at residue 537 or 538, whereas substantially higher doses (50-100 nM) were needed to bring activity levels closer to those of wild-type ERα. As the doses at which potent ER inhibition is achieved in the mutant-expressing models may exceed the steady-state, intratumoral levels achieved in patients, these data raise the possibility that more potent or selective ER antagonists will be required to effectively inhibit ERα mutants with alteration at residue 537 or 538.
Molecular dynamics simulation of Asp538Gly
The crystal structures of agonist-bound wild-type ERα and Tyr537Ser mutant ERα were previously determined 14, 24 . To directly examine the possible effects of the p.Asp538Gly alteration on ERα conformation, we performed molecular dynamics simulations on structures for wild-type ERα and the Tyr537Ser and Asp538Gly mutants, each in the absence of ligand and with a coactivator (TIF2) bound. The stability of each ERα variant in an agonist conformation was then assessed by the root-mean-square deviation (r.m.s.d.) between the starting agonist conformation and the final conformation after 10-ns molecular dynamics simulations. Of the three coactivator-bound ERα variants, wild-type ERα showed the largest difference from the starting agonist conformation (Fig. 4a) , with the cofactor-recruiting H12 helix (starting at residue 538) drifting away from the rest of the ERα structure (including helix 3, H3) by 2.1 Å in r.m.s.d. The Tyr537Ser mutant clearly contrasted with wild-type ERα, as its H12 helix stayed close to the starting agonist conformation (Fig. 4b) 
A r t i c l e s
with an H12 r.m.s.d. value of 1.2 Å. A hydrogen bond between the side chains of Ser537 and Asp351 was observed in the 10-ns molecular dynamics structure of the Tyr537Ser mutant (Fig. 4b, inset) . This hydrogen bond was found to be stable throughout the molecular dynamics simulation and existed for 99.8% of the last 1 ns (Fig. 4d) . In other studies, the p.Tyr537Ser alteration was introduced to facilitate structural determination of ER-agonist complexes, and the hydrogen bond with Asp351 was observed in corresponding X-ray crystal structures 14 .
In the case of the Asp538Gly mutant, the starting residue 538 of the H12 helix shifted toward the H3 helix by 3.5 Å (Fig. 4c) . Remarkably, hydrogen bonds were formed between the backbone of Gly538 (with a nitrogen atom acting as a donor) and the side chain of Asp351 (with two oxygen atoms acting as acceptors). For simplicity, a single distance between the hydrogen and its closer acceptor at Asp351 was measured for each snapshot of the simulations. Judging by a standard 2.4-Å cutoff in hydrogen-to-acceptor distance, Gly538-Asp351 hydrogen bond(s) were stable during the simulation and existed for 94.3% of the last 1 ns (Fig. 4d) . In contrast, no hydrogen bond was found between Gly538 and Asp351 in wild-type ERα, either in the crystal structure or during the simulation. Even though the rest of the H12 helix drifted away from the H3 helix by 2.8 Å, we speculate that the hydrogen bonds can keep H12 from moving substantially further away from its agonist conformation. Judging from the slightly longer hydrogen-to-acceptor distances and lower existence percentage in the last 1 ns of simulations, the Gly538-Asp351 hydrogen bond(s) in the Asp538Gly mutant appeared weaker than those between Tyr537Ser and Asp351. The Gly538-Asp351 hydrogen bond(s) were very likely enabled by the substituent glycine, which is the smallest and most flexible of all natural amino acids and can adopt backbone conformations inaccessible to other amino acids. Indeed, this hypothesis was supported by the unique φ angle (the dihedral around an N-C α bond) at residue 538 modeled for the Asp538Gly mutant (−125° compared to around −49° for wild-type ERα and the Tyr537Ser mutant; crystallized or simulated by molecular dynamics). This hypothesis was further supported by a functional experiment in which mutating residue 538 to an alanine (uncharged and small like glycine) had no effect on ER transactivation function (Supplementary Fig. 7) .
Taken together, the conformational choices of wild-type ERα and the Tyr537Ser and Asp538Gly mutants correlated with their basal activity levels and provide a mechanistic explanation for the newly discovered activating alteration p.Asp538Gly.
DISCUSSION
In this report, we identify for the first time, to our knowledge, recurrent mutations of ESR1 affecting its LBD in approximately 20% of metastatic ER-positive breast cancers. The mutations occur in a population of patients with hormone-refractory disease. Our biochemical and structural data demonstrate that these mutations promote the agonist conformation of ERα in the absence of ligand and likely represent one of the major causes of acquired resistance to estrogen depletion therapies such as aromatase inhibitors. The mutants appear to retain some sensitivity to drugs directly targeting the receptor, suggesting potential pharmacological strategies for patients with these mutant receptors.
A natural LBD mutation of ESR1 was first described in a patient with metastatic breast cancer in 1997 (ref. 15) . Subsequent studies interrogating the exomes and genomes of primary breast cancers have failed to identify similar lesions, causing many to question whether the initial finding was merely an outlier 7 . In our study of metastatic breast cancer samples, we identified 9 of 36 tumors with mutations affecting the LBD of ERα. Independently, analysis of ER-positive metastatic breast cancers from the BOLERO-2 trial also identified 5 of 44 patients with ESR1 mutations affecting its LBD. In many regards, these two studies were highly comparable, with alterations in the same amino acids, lack of alterations in other domains of the protein and mutations found in patients with prolonged exposure to hormonal therapy. There are two obvious differences between these two metastatic tumor cohorts and the primary tumors in which few or no ESR1 mutations were found. First, analyzing metastatic tumors rather than primary tumors enforced a selection bias for more aggressive and lethal tumors. Second, in our population, patients with ESR1 mutations were exposed to an average of 5 years of hormonal therapy. Our selection of this population was imposed to facilitate understanding of a specific and understudied clinical entity, patients with acquired resistance to hormonal therapy.
In our analysis of frequently mutated oncogenes and tumor suppressors, ESR1 mutations stood out as a common and plausible event that could contribute to resistance. We found that the mutations affecting both Tyr537 and Asp538 strongly promoted ER signaling in the absence of ligand. This effect was observed biochemically as increased phosphorylation of Ser118, increased association with AIB1 and diminished sensitivity to HSP90 inhibitors. Functionally, the mutations promoted the expression of classical ER target genes in vitro in the absence of hormone. Moreover, expression of the Tyr537Ser or Asp538Gly mutant was sufficient to render a hormonesensitive tumor model, MCF-7 cells, resistant to estrogen deprivation in vivo. Interestingly, the Ser463Pro mutant was also observed in three patients and in all cases co-occurred with alteration at Tyr537 or Asp538. Expression of the Ser463Pro mutant was associated with a rather modest induction in ER activity in the absence of hormone, as evaluated by ER target gene expression, with expression not increased to levels close to those seen with the Tyr537Ser or Asp538Gly mutant. Expression of this mutant together with Asp538Gly did induce activity above the levels seen with Asp538Gly alone. Given the location of this residue near the dimerization interface of ERα, it will be of interest to study whether the mutation alters ER dimer formation and what complementary roles it might have with the Tyr537Ser and Asp538Gly mutants in mediating hormone resistance.
Computer modeling of the structural effects of the p.Tyr537Ser and p.Asp538Gly alterations helped to decipher the molecular mechanisms responsible for the hormone-independent activities of the mutants. Molecular dynamics stimulations of the Tyr537Ser and Asp538Gly mutants bound to TIF2 (a coactivator) showed that both mutants favor formation of the agonist conformation of ERα (Fig. 4) . Provocatively, hydrogen bonds were detected between Gly538 or Ser537 and Asp351 (on H3), which existed for 94.3% and 99.8% of the last 1 ns of stimulation, respectively. Formation of the latter bond is validated in the crystal structure of the Tyr537Ser mutant and is associated with the constitutive activity of the mutant 14 . The newly discovered hydrogen bond involving Gly538 is likely caused by altered backbone conformations inaccessible to all natural amino acids except glycine, a hypothesis supported by the fact that the Asp538Ala mutant was non-activating. Furthermore, these stimulations agree with the activity levels of the mutants, suggesting that these hydrogen bonds stabilize the agonist conformation, especially for the coactivatorrecruiting H12 helix and its surroundings, and may contribute to the elevated activity of the mutants. The simulations do not, however, show obvious effects of the alterations on the ligand-binding pocket that might hinder ER antagonists from binding. Indeed, in vitro ligand binding assays confirmed the ability of mutant LBDs to bind E2 npg (data not shown). Rather, the effects on helix H12 are likely to influence coactivator and/or corepressor binding.
Although the mutant ERα isoforms were not effectively inhibited by hormone withdrawal, they could be partially inhibited by direct antagonists of the receptor, such as tamoxifen and fulvestrant. These findings validate previously reported data on the effect of tamoxifen on the activity of the Tyr537Ser mutant 23 . However, the ability of these drugs to inhibit the mutants is somewhat impaired. When we examined the effect of different doses of these compounds on mutantexpressing cells, at the lower doses, residual activity was observed, and this activity may be sufficient to confer drug resistance. Moreover, expression of the mutants was observed to raise the dose of tamoxifen needed to inhibit MCF7 cell growth in vitro (data not shown). By way of anecdote, one of nine patients in the MSKCC set did receive treatment with direct ER antagonists (tamoxifen followed by fulvestrant) after detection of this mutation and had no tumor response to either.
The fact that higher doses of fulvestrant and tamoxifen were able to fully antagonize mutant ERα signaling in vitro is nonetheless notable. These data and structural modeling results suggest that more potent or specific antagonists of the mutant forms may be effective at blocking ER signaling and may benefit patients where hormonal therapies can have a very high therapeutic index. As next-generation SERMs and SERDs are currently in development, analysis of their effects on the activity and stability of ERα mutants is now a pressing need given the apparent prevalence of these lesions in individuals with metastatic disease. Going further, the fact that these lesions are clearly more prevalent in metastatic disease suggests a possible causal role in this process. Given the widespread use of hormone antagonists as adjuvants to prevent metastatic recurrence, it will be important to determine whether the identified mutations can be implicated in such recurrences and, then, whether newer SERMs or SERDs that more potently block mutant function can be curative when given as adjuvants.
METHODS
Methods and any associated references are available in the online version of the paper. Accession codes. Accession codes. Gene expression array data for MCF7 cells transfected with constructs expressing wild-type or mutant ERα fused with GFP have been deposited in the Gene Expression Omnibus (GEO) under accession GSE51448. 
ONLINE METHODS
Reagents. We obtained 4-hydroxytamoxifen (4-OHT) and 17β-estradiol (E2) from Sigma-Aldrich. Fulvestrant (ICI 182780) was purchased from Selleck Chemicals, and bazedoxifene acetate (BZA) was purchased from Toronto Research Chemical. SNX2112 was obtained from Pfizer. All drugs were dissolved in ethanol except for BZA and SNX2112, which were reconstituted in DMSO. Antibodies to ER-α phosphorylated at Ser118 (11072), hemagglutinin (HA) tag (2367, 6E2), AIB1 (611105, 34/AIB-1) and β-actin (5441, AC-15) were purchased from Signalway Antibody, Cell Signaling Technology, BD Transduction Laboratories and Sigma, respectively. GFP-trap_A kit was obtained from Chromotek. pcDNA 3.1 (+), pCL-Ampho and pVSVG vectors were kind gifts from P. Chi, and pSIN-TREtight-IRES-Cherry vector was a kind gift from S. Lowe. pRL-TK Renilla Luciferase plasmid was obtained from Promega, 3×-ERE-TATA-Luciferase reporter and pEGFP-C1-ERα were obtained from Addgene (Addgene plasmids11354 and 28230, deposited by D. McDonnell and M. Mancini, respectively).
Cell culture. All cell lines were maintained at 37 °C and 5% CO 2 in a humidified atmosphere. SK-BR-3 MCF7, ZR-75-1, MDA-MB-361 and MDA-MB-231 cell lines were obtained from the American Type Culture Collection, and MCF Tet-On cells were obtained from Clontech. The Ishikawa cell line was obtained from the laboratory of J.S. Reis-Filho. SK-BR-3, MCF7 and MDA-MB-361 cells were grown in DMEM-F12, ZR-75-1 and MDA-MB-231 cells were grown in RPMI, and Ishikawa cells were grown in DMEM, supplemented with 5% heat-inactivated FBS, 100 µg/ml penicillin, 100 mg/ml streptomycin and 4 mM glutamine. MCF Tet-On cells were grown in similar medium except that FBS was replaced with 10% Tet System Approved FBS from Clontech. All cell lines tested negative for mycoplasma.
Transfections. Cells were either transfected with Lipofectamine 2000 (Invitrogen) or X-tremeGENE (Roche) according to the manufacturers' protocols. For experiments involving estrogen induction, cells were transfected in phenol red-free DMEM-F12 containing 10% charcoal-stripped FBS (hormonedepleted medium) (Invitrogen), and E2 was added 24 h after transfection.
Cloning and mutagenesis.
A sequence encoding an HA tag was inserted onto the 5′ end of ESR1 by PCR amplifying it from pEGFP-C1-ERα using the primers listed in Supplementary Table 3 . This fragment encoding HA-ERα was cloned into pcDNA3.1 (+) using ApaI and BamHI restriction sites and into pSIN-TREtight-IRES-Cherry using BamHI and ApaI restriction sites. Point mutations were introduced into pEGFP-C1-ERα, pcDNA-HA-ERα and pSINTREtight-HA-ERα using the QuikChange II XL Site-Directed Mutagenesis kit (Stratagene) as described in the manufacturer's instructions.
Clinical samples (MSKCC set).
Patients with breast cancer and either recurrence of disease after receiving adjuvant therapy or World Health Organization (WHO)-defined progression of metastatic disease on therapy were prospectively enrolled on an institutional review board (IRB)-approved tissue collection protocol from February 2007 through January 2013. Informed consent was obtained from all participants. All patients underwent biopsy of at least one site to document progressive disease. Mutational analysis of the metastatic biopsy was performed on fresh-frozen specimens. Formalin-fixed, paraffin-embedded blocks of each primary tumor before treatment were obtained, where possible, for comparison. The presence of tumor, in both frozen samples and formalin-fixed, paraffin-embedded tissue sections, was confirmed by the study pathologist. Extraction of genomic DNA was performed using a QuickGene DNA tissue kit (Fujifilm). A minimum of 5 mg of fresh-frozen tumor was suspended in 360 µl of tissue lysis buffer (MDT) to which 40 µl of proteinase K was added, and samples were incubated for 48 h at 55 °C. Lysis buffer LDT (360 µl) was then added, and samples were incubated at 70 °C for 30 min. Samples were washed with 100% ethanol and wash buffer. DNA was eluted in 50 µl of EDTA buffer. Quantification of DNA by Nanodrop Fluorospectrometer showed an average yield of 20 µg (average yield with PicoGreen was 250 ng). A prespecified effect size was not estimated in our discovery efforts using nextgeneration sequencing to characterize hormone-refractory breast cancers.
IMPACT next-generation sequencing and analysis. Extracted genomic DNA from the MSKCC clinical samples underwent next-generation sequencing using an Illumina HiSeq 2000 instrument, and analysis was performed using our custom IMPACT assay (Integrated Mutation Profiling of Actionable Cancer Targets). The IMPACT assay uses specially designed target-specific probes to capture all the protein-coding exons of 230 genes of interest for hybrid selection (Agilent SureSelect or Nimblegen SeqCap) as previously described 25 . The list of genes included commonly implicated oncogenes, tumor suppressor genes and components of pathways deemed actionable by current targeted therapies (see Supplementary Table 4 for the complete list of targets). In addition to targeting exons from the 230 cancerrelated genes, we also designed probes to target >1,000 common SNPs across the genome. For each sample, we examined all sites that were homozygous, and we calculated the average minor allele frequency across these sites. Tumors for which the average minor allele frequency at homozygous sites was >2% were removed, as this frequency suggests the presence of contaminating DNA from another individual. By closely monitoring this value and removing samples harboring evidence of contamination, we increased our confidence that variants with low allele frequencies were bona fide mutations and not false-positive artifacts.
Two protocols were followed during the course of the study. For eight samples (four tumor-normal pairs), barcoded sequence libraries (Illumina TruSeq) were prepared using 500 ng of input tumor or matched normal DNA according to the manufacturer's instructions. Libraries were pooled at equimolar concentrations (100 ng per tumor library and 50 ng per normal sample library) for a single exon capture reaction (Agilent SureSelect) as previously described 26 . For the remaining samples, barcoded sequence libraries were prepared with 250 ng of input DNA using a hybrid protocol based on the NEBNext DNA Library-Prep kit (New England Biolabs). The manufacturer's instructions were followed with two substitutions: instead of the specified reagents, we used NEXTflex barcoded adapters (Bio Scientific) and HiFi DNA polymerase (Kapa Biosystems). Libraries were pooled at 100 ng per tumor library and 50 ng per normal sample library for a single exon capture reaction (Nimblegen SeqCap). To prevent off-target hybridization in all capture reactions, we spiked libraries with a pool of blocker oligonucleotides complementary to the full sequences of all barcoded adaptors (to a final total concentration of 10 µM). Hybridized DNA was sequenced on an Illumina HiSeq 2000 instrument to generate paired-end 75-bp reads.
Data were demultiplexed using CASAVA, and reads were aligned to the reference human genome (hg19) using the Burrows-Wheeler Alignment tool 27 . Local realignment and quality score recalibration were performed using the Genome Analysis Toolkit (GATK) according to GATK best practices 28 . We achieved mean exon sequence coverage of 512× (628× for all tumor samples and 418× for all normal samples). Deep sequencing ensured sensitivity in detecting mutations in multiclonal and stroma-admixed samples and enabled accurate determination of mutation allele frequencies.
Sequence data were analyzed to identify three classes of somatic alterations: single-nucleotide variants, small insertions-deletions (indels) and copy number alterations. Single-nucleotide variants were called using muTect 29 and retained if variant allele frequency in the tumor was >5 times that in the matched normal sample. Indels were called using the SomaticIndelDetector tool in GATK. All candidate mutations and indels were reviewed manually using the Integrative Genomics Viewer 30 . Mean sequence coverage was calculated using the DepthOfCoverage tool in GATK and was used to compute copy number as described previously 6 .
Clinical samples (BOLERO-2 sample set). The study design for BOLERO-2 has been described previously 13 . Archival tissue samples with sufficient tumor content (10 slides per patient) were identified and analyzed by nextgeneration sequencing.
Foundation Medicine next-generation sequencing and analysis (BOLERO-2 set). Next-generation sequencing and analysis by Foundation Medicine was performed as described previously 31 . DNA sequencing was performed on 3,230 exons from 182 cancer-related genes on indexed, adaptor-ligated, hybridization-captured (Agilent SureSelect custom kit) libraries using DNA isolated from 272 formalin-fixed, paraffin-embedded tumors along with matched normal DNA from white blood cells. A total of 227 samples (183 primary and 44 metastatic) with coverage of >250× and average coverage of 602 ± 202× were included in the final analysis.
Retroviral infection and generation of stable cell lines. We plated 293CT packaging cells at 2.5 × 10 7 cells/ tissue culture dish (10 cm in diameter) and npg transfected them with 2.25 µg of the pSIN-TREtight retroviral vector (empty or encoding HA-tagged wild-type or mutant ERα), 2.25 µg of pCL-Ampho and 0.5 µg of pVSVG with X-tremeGENE (Roche) according to the manufacturer's protocol. Conditioned medium containing recombinant retroviruses was collected and filtered through non-pyrogenic filters with a pore size of 0.45 µm (Millipore). Samples of these supernatants were applied immediately to MCF Tet-On cells, which had been plated 18 h before infection at a density of 4 × 10 6 cells/tissue culture dish (10 cm in diameter). Polybrene (Sigma) was added to a final concentration of 8 µg/ml, and supernatants were incubated with cells for 12 h. After infection, cells were placed in fresh growth medium and cultured as usual. Selection with 500 µg/ml hygromycin was initiated 72 h after infection. After 14 d of selection, the hygromycin concentration was lowered to 100 µg/ml, and cells were cultured as usual.
Mouse studies. We obtained 6-to 8-week-old nu/nu athymic BALB/c female mice from Harlan Laboratories and maintained them in pressurized, ventilated caging. All studies were performed in compliance with institutional guidelines under an institutional animal care and use committee (IACUC)-approved protocol (MSKCC 12-10-016). Xenograft tumors of MCF7 cells inducibly expressing HA-ERα were established in nude mice by subcutaneously implanting 0.72 mg of sustained-release 17β-estradiol pellets with a 10-g trocar into one flank and injecting 1 × 10 7 cells suspended 1:1 in reconstituted basement membrane (Matrigel, Collaborative Research) into the opposite flank 3 d later. We removed 17β-estradiol pellets from the mice when tumors reached a size of ~250 mm 3 , and mice then received water containing 0.2 or 0.5 mg/ml doxycycline (0.2 mg/ml for mice with xenografts expressing wild-type ERα and 0.5 mg/ml for mice with xenografts expressing vector control or Tyr537Ser or Asp538Gly mutant ERα) and 0.1% sucrose for induction of ER expression 7 d after pellet removal. Tumor dimensions were measured with vernier calipers, and tumor volume was calculated (π/6 × larger diameter × (smaller diameter) 2 ). In this study, no blinding of investigators or randomization of mice was performed. On the basis of our previous work measuring the variability in size and growth of MCF7 xenografts, we estimated that ten mice per group would allow us to detect differences in tumor size of >200 mm 3 .
Coimmunoprecipitation. Coimmunoprecipitation was performed with the GFP-Trap_A kit according to the manufacturer's protocol. In brief, cell pellets were resuspended in coimmunoprecipitation lysis buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 0.5% NP-40 and 1× protease and phosphatase inhibitors (Pierce)). Cells were lysed by pipetting the pellet up and down every 10 min for a total of 30 min while on ice. Lysates were cleared by spinning them at 20,000g for 10 min. For coimmunoprecipitation, 1 mg of lysate was used for each sample with 100 µl of equilibrated GFP-Trap_A beads, and samples were incubated on a rotator overnight at 4 °C. Beads were then washed twice with ice-cold wash buffer, resuspended in 2× LDS sample buffer (Invitrogen) and boiled for 10 min at 70 °C before loading onto SDS-PAGE gels.
Immunoblotting. Cells were washed once with cold PBS and scraped off the plate with a rubber policeman. The cell suspension was briefly centrifuged to pellet cells, PBS was removed, and the cell pellet was stored at −80 °C until lysis. For cell lysis, pellets were resuspended in a non-denaturing lysis buffer (Cell Signaling Technology) supplemented with protease and phosphatase inhibitors (Pierce) and were sonicated briefly for 30 s. Lysates were cleared by centrifugation at 14,000g for 10 min, and protein concentration was determined using the BCA kit (Pierce), which measures the reduction of Cu 2+ to Cu 1+ by protein in an alkaline medium. For each sample, 30 µg of protein lysate was loaded onto 4-12% SDS-PAGE minigels (Invitrogen) for electrophoresis and immunoblotting.
Luciferase assays. Cells were plated at a density of 0.1 × 10 6 cells per well of a 24-well plate 1 d before transfection. Cells were transfected with 100 ng (per well) of vector encoding HA-tagged wild-type or mutant ERα, 250 ng (per well) of 3×-ERE-TATA-Luciferase reporter and 50 ng (per well) of pRL-TK Renilla Luciferase plasmid using Lipofectamine 2000. Cells were treated with either E2, 4-OHT or ICI 1 d after transfection for 24 h, and luciferase activities were determined using the Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's instructions. Luciferase bioluminescence measurements were performed with the Veritas Microplate Luminometer (Promega). All experiments were conducted in triplicate, and firefly luciferase activity was normalized by Renilla luciferase activity for each sample.
Quantitative RT-PCR. RNA was extracted from cells 48 h after transfection using the RNeasy Mini kit (Qiagen) according to the manufacturer's protocol. cDNA was synthesized with 2 µg of RNA from each sample using the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen) according to the manufacturer's protocol. Synthesized cDNA was diluted with one volume of DEPC-treated water, and 2 µl of the mixture was added to TaqMan PCR Master Mix (Applied Biosystems) along with primers. Relative quantification for each mRNA was performed using the comparative C T method with a ViiA 7 Real-Time PCR system (Applied Biosystems) 32 . Samples were run in triplicate, and mRNA levels were normalized to those of ESR1 for each reaction.
Microarrays. RNA was extracted from MCF7 cells transfected with vector expressing wild-type or mutant ERα fused with GFP using TRIzol reagent and was analyzed with the HumanHT-12 v4 Expression BeadChip (Illumina). Statistical analysis of differences between groups was performed using standard ANOVA tests. Data were analyzed using the Partek Genomics Suite.
Molecular dynamics simulations.
Crystal structures for TIF2-bound wild-type and Tyr537Ser ERα were obtained from PDB 6 (accessions 1GWQ and 3Q95, respectively), and corresponding agonist ligands were removed. A few terminal residues of ERα or TIF2 were also removed so that the two structures shared the same segment. The structure of TIF2-bound Asp538Gly ERα was first constructed by removing the side chain atoms at residue 538. For all three structures, missing atoms were placed with geometries parameterized by CHARMM22 (ref. 33 ) and were then minimized, with the rest harmonically constrained, using the molecular modeling program CHARMM 34 . Minimization was performed with a distance-dependent dielectric constant to approximate solvation effects. No distance cutoff for non-bonded interactions was used.
The resulting structures were used as starting points for explicit-solvent molecular dynamics simulation. Each was first placed in a water box whose boundaries were at least 15 Å away from the nearest ERα or TIF2 atoms. Sodium and chloride ions were also added to reach a physiological concentration (0.145 M) and total charge neutrality. The two steps above were performed with the program VMD 35 . Each system of TIF2-bound ERα (wild type, Tyr537Ser or Asp538Gly), water molecules and ions was minimized for 5,000 steps and then run for a 10-ns molecular dynamics stimulation using the program NAMD 36 . Constant temperature (300 K) and pressure (1 atm, with the Nosé-Hoover Langevin piston method) were used for the molecular dynamics simulations. Force-field parameters were adopted from CHARMM22. Electrostatic interactions were treated with a particle mesh Ewald (PME) method (1-Å grid spacing and 14-Å distance cutoff). Dynamics were run with a 2-fs time step, and the list of non-bonded interactions was updated every ten steps.
Statistics.
All reported values represent the average of triplicate experiments. Statistical analysis of differences between samples was performed using standard two-tailed Student's t tests, and P < 0.05 was defined as significant. Analysis was conducted using Prism v6.0c (GraphPad Software).
